2020. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s83. DOI:https://doi.org/10.25251/skin.4.supp.83.